KDR and heart failure: Ponatinib, sorafenib, and sunitinib can target VEGFR2 and PDGFRs, so that cause high-levels of cardiotoxicity, such as hypertension, heart failure, myocardial infarction, and cardiac arrhythmias (Table S1).